Bartholin's gland squamous cell carcinoma is a rare vulvar cancer that starts in a small gland near the vaginal opening. People with this condition may notice a persistent lump, pain with sitting or sex, or bleeding, and doctors may see a firm mass that does not resolve. It mainly affects adults, often after menopause, and it can grow locally and sometimes spread if not treated. Treatment usually includes surgery, and may also involve radiation and chemotherapy. The outlook varies with stage at diagnosis, but many people do well when Bartholin's gland squamous cell carcinoma is found early and treated promptly.
Overview
Bartholin's gland squamous cell carcinomaSymptoms
Bartholin's gland squamous cell carcinoma appears as a firm lump near the vaginal opening, sometimes mistaken for a Bartholin cyst. Early symptoms include vulvar pain, swelling, bleeding, or discharge, and discomfort with walking, sitting, or sex. Groin lumps can occur.
Outlook and prognosis
Outlook for Bartholin's gland squamous cell carcinoma depends on stage at diagnosis, tumor size, and whether lymph nodes are involved. When found early and fully removed, long-term control is possible. Regular follow-up helps catch recurrences or new symptoms promptly.
Causes and risk factors
Bartholin's gland squamous cell carcinoma is mainly linked to persistent high‑risk HPV infection; risks rise with age (especially after menopause), smoking, immunosuppression, and chronic vulvar inflammatory conditions. Prior cervical/vulvar precancer or cancer also increases risk; inherited risk is uncommon.
Genetic influences
Genetics play a limited role in Bartholin's gland squamous cell carcinoma. Most cases arise from long-term local factors like chronic inflammation or HPV, not inherited mutations. Routine genetic testing isn’t standard; tumor profiling may guide targeted therapy in select advanced cases.
Diagnosis
Doctors start with a pelvic exam and history, noting any vulvar mass. Imaging (ultrasound or MRI) helps define the area and spread. A biopsy confirms the diagnosis of Bartholin's gland squamous cell carcinoma and guides staging and treatment.
Treatment and drugs
Treatment for Bartholin's gland squamous cell carcinoma often combines surgery to remove the tumor and nearby tissue with lymph node evaluation. Many also receive radiation therapy, sometimes with chemotherapy, to lower recurrence risk. Care teams tailor plans to tumor size, spread, and personal goals.
Symptoms
A new lump or sore near the vaginal opening is often the first change people notice. Early symptoms of Bartholin's gland squamous cell carcinoma can look like a simple Bartholin cyst or abscess, which is why it’s easy to miss at first. Symptoms vary from person to person and can change over time. Pain with sitting, walking, or sex, unexpected bleeding, or a firm area that doesn’t go away deserve attention.
A new, firm bump near the vaginal opening, often on one side, is a common first sign. In Bartholin's gland squamous cell carcinoma, the lump may feel hard or fixed and doesn’t go away.
Aching or sharp pain low on one side of the vulva can build over days or weeks. Sitting, walking, cycling, or sex can make it worse.
A sore, crack, or wart-like spot that doesn’t heal can show up on the skin. It may bleed, crust, or feel tender to the touch.
A sense of fullness or swelling in the area can develop even without a clear bump you can feel. Clothing or underwear may rub and irritate the spot.
How people usually first notice Bartholin's gland squamous cell carcinoma?
People usually first notice Bartholin’s gland squamous cell carcinoma as a firm, persistent lump or swelling near the vaginal opening that doesn’t go away with warm compresses or typical Bartholin cyst treatments. Pain during sitting, walking, or sex, new bleeding, or a sore that ulcerates can be early clues, especially if the “cyst” recurs on the same side or feels unusually hard. Doctors often become concerned when a Bartholin “cyst” appears in people over age 40, grows quickly, or has irregular borders, prompting a biopsy to confirm the diagnosis—these are the first signs of Bartholin’s gland squamous cell carcinoma that lead to detection.
Types of Bartholin's gland squamous cell carcinoma
Bartholin's gland squamous cell carcinoma is rare, and clinicians often describe it by where it starts and how it looks under the microscope. Broadly, symptoms are grouped into patterns that reflect the tumor’s location and behavior, which can affect pain, swelling, and nearby tissues. Symptoms don’t always look the same for everyone. When people search for types of Bartholin's gland squamous cell carcinoma, they’re often looking for how tumor patterns differ and what that means for day-to-day impact.
Localized vulvar mass
A firm lump near the vaginal opening that doesn’t go away, sometimes mistaken for a recurrent Bartholin’s cyst or abscess. Pain with sitting, walking, or sex can develop as the tumor grows. Skin changes like thickening, ulceration, or a nonhealing sore may appear.
Pain-dominant pattern
Aching or sharp pain on one side of the vulva that can radiate to the inner thigh. Discomfort may worsen with movement, tight clothing, or intercourse. Swelling or a tender spot near the Bartholin’s area often accompanies the pain.
Skin and surface changes
A rough patch, wart-like bump, or open sore that bleeds easily can form on the vulvar skin. Itching, burning, or a feeling of rawness may occur. A persistent area that looks different from the surrounding skin is a key clue.
Gland or duct blockage
Repeated “cysts” or abscess-like swellings in the Bartholin’s area that return after drainage can signal an underlying tumor. The lump may feel unusually hard or fixed compared with a typical cyst. Fever is less common than with true infections.
Lymph node involvement
A new, firm lump in the groin on the same side as the vulvar mass can indicate spread to nearby lymph nodes. Walking or leg movement may make the groin area feel sore or heavy. Not everyone will experience every type.
Advanced local spread
Trouble sitting, persistent bleeding, or discharge with a foul odor can occur if nearby tissues are involved. The tumor may extend to adjacent structures, leading to more constant pain. Fatigue or weight loss can appear later as symptoms build.
What genetics can tell you about symptoms
Some people with certain TP53 or CDKN2A gene changes may notice faster-growing Bartholin’s gland squamous cell carcinoma, with earlier lumps, pain, or bleeding. These variants can act like a stuck accelerator for cell growth, making tumors more aggressive and harder to treat.
Causes and risk factors
This cancer is rare, and a single clear cause is often not found. High-risk human papillomavirus (HPV) has been linked to a higher chance of Bartholin's gland squamous cell carcinoma. Risk is higher with age over 40, smoking, weakened immunity, and long-standing vulvar skin conditions such as lichen sclerosus. Doctors distinguish between risk factors you can change and those you can’t. Family history is not a known driver, so inherited risk factors for Bartholin's gland squamous cell carcinoma appear low.
Environmental and biological risk factors
Environmental and biological risk factors for Bartholin's gland squamous cell carcinoma can be easy to miss in day-to-day life. Doctors often group risks into internal (biological) and external (environmental). Understanding these can help you know when to schedule a checkup or ask for a closer look if a vulvar lump changes. The points below highlight body-based features and outside exposures tied to higher risk.
Risk of Bartholin's gland squamous cell carcinoma rises in midlife and beyond, especially after menopause. Age-related changes in vulvar tissue and immune surveillance can make abnormal cells more likely to grow.
Exposure to high-risk human papillomavirus can trigger cell changes near the Bartholin gland. This virus is a well-known driver of squamous cell cancers in the vulvar area.
When HPV infection does not clear for years, the ongoing viral activity can cement DNA damage. This persistence increases the likelihood of Bartholin's gland squamous cell carcinoma developing over time.
A weakened immune system has a harder time clearing HPV and repairing early cell damage. Conditions like HIV or long-term immune-suppressing medicines can therefore raise the risk of squamous cancers in the vulvar region.
Genetic risk factors
Genetic risk factors for Bartholin's gland squamous cell carcinoma are not well defined because this cancer is very rare. Most cases seem to arise sporadically from DNA changes within the tumor rather than inherited variants. Similar to other vulvar squamous cancers, changes affecting TP53, cell cycle control, and PI3K/AKT signaling have been described in Bartholin gland tumors. Carrying a genetic change doesn’t guarantee the condition will appear.
Sporadic tumor mutations: Most Bartholin's gland squamous cell carcinomas develop from acquired DNA changes in the tumor, not ones you were born with. These somatic changes drive cells to grow and divide abnormally.
TP53 alterations: Mutations in TP53 have been identified in some Bartholin gland and other vulvar squamous tumors. They can disable a key checkpoint that helps repair DNA damage and control cell division.
Cell cycle genes: Changes in genes that regulate the cell cycle, such as CDKN2A, occur in vulvar squamous cancers and have also been reported in Bartholin region tumors. Disruption of these genes removes important brakes on growth.
PI3K/AKT pathway: Alterations in PIK3CA or PTEN can switch on growth signals that help tumor cells survive. Similar findings have been noted in some vulvar and Bartholin gland squamous cancers.
NOTCH/HRAS changes: Mutations in NOTCH1 or HRAS appear across squamous cell cancers, including vulvar sites. When present, they can shift how cells mature and respond to growth cues.
DNA repair syndromes: Rare inherited conditions like Fanconi anemia increase the risk of anogenital squamous cancers, which may include the Bartholin area. People with these syndromes should discuss individualized screening plans with their care team.
Xeroderma pigmentosum: This inherited DNA-repair disorder raises the chance of squamous cancers on skin and sometimes the anogenital tract. Only isolated reports link it to vulvar or Bartholin tumors, but it signals greater susceptibility overall.
Family history clues: There is no typical family pattern for Bartholin's gland cancer. A strong family history of early or multiple squamous cancers may warrant genetics input even though most cases are not hereditary.
Tumor testing insights: Testing the tumor’s DNA can show which pathways are altered. These results do not prove an inherited risk unless a separate germline test finds the same change in your blood or saliva.
Lifestyle risk factors
Bartholin's gland squamous cell carcinoma is rare, so evidence comes mostly from research on vulvar squamous cell carcinoma that includes the Bartholin region. The clearest lifestyle risk factors for Bartholin's gland squamous cell carcinoma relate to exposure to high‑risk HPV, tobacco use, and behaviors that influence immune function. These factors do not guarantee cancer but can change the chances that precancerous changes appear or persist. Below are practical ways how lifestyle affects Bartholin's gland squamous cell carcinoma, highlighting lifestyle risk factors for Bartholin's gland squamous cell carcinoma.
Tobacco smoke reduces local immune defenses and helps high‑risk HPV persist in vulvar and Bartholin gland tissues. Persistent HPV makes squamous cell changes more likely to progress to cancer.
Early sexual debut and multiple partners increase exposure to high‑risk HPV types. Greater HPV exposure raises the chance of vulvar and Bartholin gland squamous cell carcinoma over time.
Inconsistent condom use allows more HPV transmission between partners. Regular condom use lowers, but does not eliminate, HPV spread and may reduce future risk in the Bartholin region.
Skipping vaccination leaves you unprotected against high‑risk HPV strains linked to vulvar and Bartholin gland cancers. Getting vaccinated before exposure markedly reduces future cancer risk.
Risk prevention
Bartholin's gland squamous cell carcinoma is rare, so there isn’t a single proven way to stop it entirely. Prevention is about lowering risk, not eliminating it completely. Reducing exposure to high‑risk HPV, caring for vulvar skin, and getting any new gland swelling checked promptly may help. Regular pelvic exams can also raise the chances of finding problems early.
Getting the HPV vaccine lowers the risk of HPV‑related vulvar cancers. It’s recommended for many people up to age 26, and may be considered up to age 45 depending on your health history.
Using condoms and dental dams can reduce, though not fully prevent, HPV transmission. Limiting new partners and avoiding smoking or vaping during sex-related activities may also help lower risk.
Tobacco weakens local immune defenses and is linked with higher risk of vulvar squamous cell cancers. Stopping smoking or vaping can support your body’s ability to clear HPV and heal skin.
Conditions like lichen sclerosus raise vulvar cancer risk if left untreated. Regular treatment and check‑ins with a clinician can lower inflammation and reduce long‑term risk.
Transmission
Bartholin's gland squamous cell carcinoma is not contagious; you cannot give it to a partner or catch it from someone else. It does not spread through sex, kissing, casual touch, toilet seats, or shared towels, and there is no airborne or blood-borne transmission. Questions about how Bartholin's gland squamous cell carcinoma is spread come up often, but cancer cells from this tumor cannot take hold in another healthy person. It is also not typically inherited; most cases arise on their own rather than being passed down in families. While some vulvar cancers are linked to high-risk HPV infection, that infection is a risk factor for tumor development—not person-to-person spread of the cancer itself.
When to test your genes
Bartholin’s gland squamous cell carcinoma is not typically linked to inherited gene mutations, so routine genetic testing isn’t usually needed. Consider testing if there’s a strong family history of related cancers (vulvar, cervical, head/neck) or unusually early onset. If you already have this cancer, tumor DNA testing can guide targeted therapy and clinical trials.
Diagnosis
A firm, persistent lump near the vaginal opening is often the first clue, especially if it doesn’t behave like a usual Bartholin’s cyst or keeps coming back. Doctors usually begin with a careful conversation and exam, then add tests to confirm the cause and map out next steps. Because this cancer is rare and often mimics common cysts, the diagnosis of Bartholin's gland squamous cell carcinoma relies on a biopsy to be certain. Early imaging helps show whether it’s confined to the gland or has affected nearby tissues or lymph nodes.
Your provider asks when the lump started, whether it’s painful, and if it changed after drainage or antibiotics. They’ll note bleeding, discharge, and any trouble with sitting, walking, or intimacy.
The vulva and vaginal area are checked for a firm mass near the Bartholin’s gland. The doctor gently feels for tenderness and assesses size, firmness, and how the mass moves with surrounding tissue.
The skin is examined for color changes, ulceration, or irregular borders that can hint at a tumor rather than a simple cyst. Visible swelling of the gland area that does not resolve raises concern for carcinoma.
A small tissue sample is taken from the lump, often with a punch or excisional biopsy under local anesthesia. Pathology confirms squamous cell carcinoma and rules out look-alikes like cysts or other vulvar cancers.
Stages of Bartholin's gland squamous cell carcinoma
Doctors stage Bartholin's gland squamous cell carcinoma using the same system as other vulvar cancers to describe how far it has spread and to guide treatment. Understanding the stages of Bartholin's gland squamous cell carcinoma can help you and your team plan the next steps. Many people feel reassured knowing what their tests can—and can’t—show.
Stage I
Localized tumor. The cancer is limited to the Bartholin’s gland area or nearby vulvar tissue. It has not reached the vagina, urethra, anus, or lymph nodes.
Stage II
Nearby spread. The cancer has grown into nearby areas such as the lower vagina, lower urethra, or anus. Lymph nodes in the groin are still free of cancer.
Stage III
Lymph nodes involved. The cancer may be in the vulva or nearby areas and has spread to groin (inguinal/femoral) lymph nodes. Node findings help determine how much treatment is needed.
Stage IV
Advanced spread. The cancer has reached deeper structures like the upper urethra or upper vagina, bladder or rectum, the pelvic bone, or has spread to distant organs. At this stage, treatment focuses on control, symptom relief, and, when possible, shrinking or removing cancer where it appears.
Outlook and prognosis
Looking ahead can feel daunting, but most people want to know what the future may hold after a diagnosis of Bartholin's gland squamous cell carcinoma. The outlook is not the same for everyone, but factors like tumor size, whether it has spread to nearby lymph nodes, and how completely it can be removed with surgery shape the path ahead. When doctors talk about “remission,” they mean symptoms have eased or disappeared for a while, and many people do reach periods like this after treatment.
For early-stage Bartholin's gland squamous cell carcinoma that’s fully removed and treated as needed with radiation or chemotherapy, long-term control is possible and survival rates are relatively favorable compared with more advanced stages. If cancer has traveled to the groin lymph nodes or beyond, the risk of return is higher, and treatment often involves a combination of surgery, targeted radiation, and systemic therapy to improve outcomes. Many people find that symptoms such as pain, swelling, or a new lump improve within weeks to months after treatment, though close follow-up is key to catching early signs of recurrence.
Understanding the prognosis can guide planning and help you focus on what you can do now. Early symptoms of Bartholin's gland squamous cell carcinoma can be subtle, so keeping regular follow-up and reporting any new pain, bleeding, or changes in a vulvar lump matters. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, but for this cancer, stage at diagnosis and response to therapy are the strongest drivers. Talk with your doctor about what your personal outlook might look like, including your stage, lymph node status, and any clinical trials that could expand options.
Long-term effects
Bartholin's gland squamous cell carcinoma can have lasting effects from the cancer itself and from treatments like surgery and radiation. Long-term effects vary widely, and they often depend on tumor stage, lymph node involvement, and which therapies were needed. Because early symptoms of Bartholin's gland squamous cell carcinoma can be subtle, long-term follow-up focuses on spotting new changes early. Specialists usually recommend regular check-ins over the years to monitor healing and catch any recurrence.
This cancer can come back locally in the vulvar area or in nearby lymph nodes. The chance of recurrence after Bartholin's gland squamous cell carcinoma depends on stage and node findings.
Swelling of one or both legs or the vulva can develop after lymph node surgery or radiation. It may cause heaviness, tightness, and aching that fluctuates day to day.
Anatomy changes, tenderness, and nerve effects can lower arousal and make sex uncomfortable. These changes may be long-lasting after Bartholin's gland squamous cell carcinoma treatment.
Ongoing burning, soreness, or sharp twinges can follow surgery or radiation. For some, sitting, cycling, or wearing snug clothing becomes uncomfortable.
How is it to live with Bartholin's gland squamous cell carcinoma?
Living with Bartholin’s gland squamous cell carcinoma can feel disruptive at first, especially if pain, swelling, or changes in the vulvar area make sitting, walking, or intimacy uncomfortable. Treatments like surgery, radiation, or chemotherapy may bring fatigue and temporary changes in body image or sexual function, so planning rest, gentle movement, and open conversations about comfort and desire can help. Many find it useful to coordinate practical support—rides to appointments, help with errands, and flexible work arrangements—while leaning on a care team familiar with vulvar cancers. For partners, friends, and family, listening without judgment and checking in about what feels supportive can make daily life steadier for everyone.
Treatment and drugs
Treatment for Bartholin's gland squamous cell carcinoma typically centers on surgery to remove the tumor with a clear margin of healthy tissue; this may include partial or complete removal of the vulva in the affected area and nearby lymph nodes in the groin to check for spread. Depending on tumor size, depth, and lymph node results, doctors may recommend radiation therapy, sometimes with chemotherapy, to lower the risk of the cancer coming back. Not every treatment works the same way for every person, so your team will tailor the plan to your stage, overall health, and personal preferences. Alongside medical treatment, lifestyle choices play a role, including careful wound care after surgery, pelvic floor support, and sexual health counseling to help with comfort and recovery. Keep track of how you feel, and share this with your care team, especially if you notice new pain, swelling, skin changes, or side effects from treatment.
Non-drug treatment
Treatment plans for Bartholin's gland squamous cell carcinoma center on removing or controlling the tumor and protecting sexual and urinary function, with recovery supports woven in. Non-drug treatments often lay the foundation for care, from surgery and radiation to rehabilitation and counseling. Because early symptoms of Bartholin's gland squamous cell carcinoma can be mistaken for a simple Bartholin’s cyst, many people are diagnosed after a biopsy and then move quickly to local treatments. Your team will tailor choices to the tumor’s size, location, and whether nearby lymph nodes are involved.
Surgeons remove the tumor with a margin of healthy tissue to lower the chance of it coming back. Depending on size and location, this may be a wide local excision or a more extensive vulvar surgery aimed at preserving function where possible.
A tracer helps identify the first groin node(s) likely to catch cancer cells. If these sentinel nodes are clear, you may avoid a larger lymph node removal.
If cancer is found in sentinel nodes—or mapping isn’t feasible—surgeons remove more lymph nodes in the groin. This improves staging and control but can raise the risk of leg swelling (lymphedema).
Targeted radiation treats the vulva and groin to kill remaining cancer cells or shrink a tumor when surgery isn’t possible. It may be used before surgery to downsize a tumor or after surgery to reduce recurrence risk.
Your genes may have an impact on how drugs work for you
Just as people metabolize caffeine differently, genes can change how your body processes pain medicines, anesthesia, and chemotherapy for Bartholin’s gland squamous cell carcinoma. Pharmacogenetic testing may guide safer dosing or drug choice, while your care team still tailors decisions to you.
Pharmacological treatments
Drug therapy for Bartholin's gland squamous cell carcinoma is usually paired with surgery and/or radiation, especially when the cancer is locally advanced or has spread. In many cases, first-line chemotherapy for Bartholin's gland squamous cell carcinoma uses combinations that are also standard for other vulvar cancers. Not everyone responds to the same medication in the same way. Your oncology team will tailor choices based on stage, tumor markers, other health conditions, and your goals for treatment.
Low-dose cisplatin is often given once weekly during radiation to make the cancer cells more sensitive to the radiation. This approach is commonly used for tumors that can’t be fully removed or need downsizing before surgery. Doctors adjust treatment plans regularly based on tolerance and response.
This combination is a common first-line systemic chemotherapy for advanced or recurrent disease. It can shrink tumors and help control symptoms such as pain or bleeding. First-line medications are those doctors usually try first, based on how well they work and side-effect profiles.
Cisplatin may be paired with 5-fluorouracil (5-FU) as another platinum-based regimen. It’s used in some centers when combination therapy is appropriate and the goal is tumor control. Side effects, if they occur, can often be managed with dose timing, hydration, and supportive care.
For those who are frail or have other health concerns, one drug at a time—such as paclitaxel or cisplatin—may be chosen. This can reduce side effects while still offering disease control. If one option isn’t effective, second-line or alternative drugs may be offered.
Genetic influences
Most cases of Bartholin's gland squamous cell carcinoma do not run in families and are not caused by an inherited gene change. It’s natural to ask whether family history plays a role. In most people, the cancer develops because of changes that build up over time in the cells of the gland or nearby vulvar tissue, and high-risk human papillomavirus (HPV) may contribute in some cases. These acquired changes are usually limited to the tumor itself, meaning they aren’t present in your bloodline and aren’t passed to children. There isn’t a clear link between Bartholin's gland squamous cell carcinoma and known inherited cancer syndromes, though if your family has several cancers at young ages, a genetics consult can help clarify personal risk. Genetics doesn’t change what the early symptoms of Bartholin’s gland squamous cell carcinoma feel like, but understanding your background can guide treatment and follow-up choices for you and sometimes inform relatives.
Is Bartholin's gland squamous cell carcinoma genetic?
Genetics play a limited role in Bartholin's gland squamous cell carcinoma. Most cases arise from long-term local factors like chronic inflammation or HPV, not inherited mutations. Routine genetic testing isn’t standard; tumor profiling may guide targeted therapy in select advanced cases.
Pharmacogenetics—how genetics influence drug effects
For many people starting treatment, the biggest questions are which drugs will help and how tough the side effects might be. In Bartholin's gland squamous cell carcinoma, care often centers on surgery and radiation; when chemotherapy is used, your genes can sometimes influence safety and dosing. Changes in a gene called DPYD can make 5‑fluorouracil (5‑FU) or capecitabine break down too slowly, which raises the risk of severe mouth sores, diarrhea, and low blood counts; if this is found, doctors may lower the dose or choose a different drug. Genetic testing can sometimes identify how your body handles these medicines, helping your team tailor the plan. On the tumor side, labs may look for features such as DNA repair problems (mismatch repair deficiency/MSI‑high) or a high number of DNA changes (high tumor mutational burden), which can open the door to immunotherapy that’s approved across many cancer types. Because this cancer is rare, evidence is limited, so genetic testing to guide treatment for Bartholin's gland squamous cell carcinoma often follows standards used for related gynecologic squamous cell cancers.
Interactions with other conditions
Bartholin’s gland squamous cell carcinoma often intersects with other vulvar and genital conditions in ways that affect diagnosis and care. Human papillomavirus (HPV)–related changes of the cervix, vagina, or vulva can occur alongside this cancer, and immune suppression from HIV or certain medications can raise the chance of persistent HPV and make infections harder to clear. Chronic vulvar skin conditions like lichen sclerosus or ongoing irritation may complicate the picture and sometimes mimic early symptoms of Bartholin’s gland squamous cell carcinoma, while recurrent Bartholin’s cysts or abscesses can mask a tumor or delay evaluation. Other health issues—such as diabetes, poor circulation, or smoking—may slow wound healing after surgery and increase the risk of infections or radiation skin reactions, and blood thinners or steroids can influence procedure planning and recovery. If multiple issues are present, coordinated care with gynecologic oncology, infectious disease, dermatology, and primary care helps align treatments and avoid medications that work against each other. Talk with your doctor about how your conditions may influence each other.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns that some vulvar growths behaved differently—slow to appear, then stubbornly persistent—long before there were clear names for them. Midwives and surgeons described painful swellings near the vaginal opening that at times were mistaken for simple cysts or infections. In a few people, those “Bartholin cysts” returned after drainage or removal, raising concern that something else was going on.
First described in the medical literature as unusual cancers arising near the Bartholin’s gland, these cases were initially grouped together with other vulvar tumors. Early reports often labeled anything in that area as a Bartholin problem, so true Bartholin’s gland squamous cell carcinoma was hard to separate from more common conditions. Over time, pathologists learned to tell apart different cancer types under the microscope and to confirm where the tumor started, which helped define this cancer more clearly.
From these first observations, doctors began to notice that many people with Bartholin’s gland squamous cell carcinoma were first treated for what seemed like a routine Bartholin cyst or abscess. When the swelling didn’t resolve, or a firm mass recurred after surgery, tissue testing revealed squamous cell changes. As medical science evolved, consistent criteria were set: the tumor had to be located in the Bartholin’s gland region, with features matching squamous cell carcinoma and no nearby primary site that better explained it.
With each decade, surgical techniques, anesthesia, and later imaging improved, allowing more precise operations and better assessment of lymph nodes in the groin. Radiation therapy and, in selected cases, chemotherapy were added in efforts to reduce the risk of the cancer coming back. Not every early description was complete, yet together they built the foundation of today’s knowledge.
In recent decades, awareness has grown that not all vulvar cancers are the same. Some are linked to long-term irritation or skin conditions; others relate to human papillomavirus (HPV). For Bartholin’s gland squamous cell carcinoma, clinicians recognized it as rare and distinct, which encouraged specialized care and the use of tumor boards to plan treatment. Case series from cancer centers helped outline patterns—such as age at diagnosis and typical symptoms like a persistent mass or pain—that guide today’s evaluation when early symptoms of Bartholin’s gland squamous cell carcinoma resemble a common cyst.
Today, the history of this condition reminds us to take a second look when a Bartholin-area swelling behaves differently than expected. Knowing the condition’s history helps explain why a biopsy is often recommended for new or recurrent Bartholin-region masses, especially in people over midlife, and why care is best tailored by teams experienced in vulvar cancers.